Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance

Blood Cells, Molecules, and Diseases

Volumn 41, Issue 2, 2008, Pages 179-187

  Haviernik, Peter ^a   Diaz, Maria T ^b   Haviernikova, Eleonora ^a   Tse, William ^a,c   Stetler Stevenson, William G ^b   Bunting, Kevin D ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Bone marrow; Hematopoiesis; Hematopoietic progenitor mobilization; Matrix metalloproteinase; Retroviral vector

Indexed keywords

GREEN FLUORESCENT PROTEIN; MATRIX METALLOPROTEINASE; RETROVIRUS VECTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL MATURATION; CHEMOTAXIS; CONTROLLED STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STRESS;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; HEMATOPOIESIS; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

MURINAE; MUS;

EID: 48749107577     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.03.005     Document Type: Article

References (45)

1. Huang W., Meng Q., Suzuki K., et al. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. J. Biol. Chem. 272 (1997) 22086-22091
2. Murphy G., Houbrechts A., Cockett M.I., et al. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30 (1991) 8097-8102
3. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477 (2000) 267-283
4. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J. Biol. Chem. 274 (1999) 21491-21494
5. Janowska-Wieczorek A., Matsuzaki A., and Marquez A. The hematopoietic microenvironment: matrix metalloproteinases in the hematopoietic microenvironment. Hematology 4 (2000) 515-527
6. Williams D.A., Rios M., Stephens C., and Patel V.P. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 352 (1991) 438-441
7. Papayannopoulou T., and Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 9374-9378
8. Zanjani E.D., Flake A.W., Almeida-Porada G., et al. Homing of human cells in the fetal sheep model: modulation by antibodies activating or inhibiting very late activation antigen-4-dependent function. Blood 94 (1999) 2515-2522
9. van der Loo J.C., Xiao X., McMillin D., et al. VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin. J. Clin. Invest 102 (1998) 1051-1061
10. Levesque J.P., Leavesley D.I., Niutta S., et al. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J. Exp. Med. 181 (1995) 1805-1815
11. Lee M., Christopherson I.P., Lehman J.M., et al. Comparison of bone marrow extracellular matrices. Biochim. Biophys. Acta 1428 (1999) 300-304
12. Ries C., Loher F., Zang C., et al. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin. Cancer Res. 5 (1999) 1115-1124
13. Levesque J.P., Hendy J., Takamatsu Y., et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp. Hematol. 30 (2002) 440-449
14. Starckx S., Van den Steen P.E., Wuyts A., et al. Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization. Leuk. Lymphoma 43 (2002) 233-241
15. Opdenakker G., Van den Steen P.E., Dubois B., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 69 (2001) 851-859
16. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
17. Murate T., Yamashita K., Isogai C., et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br. J. Haematol. 99 (1997) 181-189
18. Tanaka A., Arai K., Kitamura Y., and Matsuda H. Matrix metalloproteinase-9 production, a newly identified function of mast cell progenitors, is downregulated by c-kit receptor activation. Blood 94 (1999) 2390-2395
19. Kossakowska A.E., Edwards D.R., Prusinkiewicz C., et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 94 (1999) 2080-2089
20. Lai C.F., Ripperger J., Morella K.K., et al. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J. Biol. Chem. 271 (1996) 13968-13975
21. Lacraz S., Nicod L.P., Chicheportiche R., et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest 96 (1995) 2304-2310
22. Guedez L., Lim M.S., and Stetler-Stevenson W.G. The role of metalloproteinases and their inhibitors in hematological disorders. Crit. Rev. Oncog. 7 (1996) 205-225
23. Alexander C.M., Hansell E.J., Behrendtsen O., et al. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 122 (1996) 1723-1736
24. Guedez L., McMarlin A.J., Kingma D.W., et al. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am. J. Pathol. 158 (2001) 1207-1215
25. Yamauchi K., Ogata Y., Nagase H., and Shirouzu K. Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg. Today 31 (2001) 791-798
26. Rigg A.S., and Lemoine N.R. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene. Ther. 8 (2001) 869-878
27. Bloomston M., Shafii A., Zervos E.E., and Rosemurgy A.S. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J. Surg. Res. 102 (2002) 39-44
28. Watanabe M., Takahashi Y., Ohta T., et al. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 77 (1996) 1676-1680
29. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. Natl. Cancer Inst. 86 (1994) 299-304
30. Koop S., Khokha R., Schmidt E.E., et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54 (1994) 4791-4797
31. Alexander C.M., Howard E.W., Bissell M.J., and Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. 135 (1996) 1669-1677
32. Yamazaki M., Akahane T., and Buck T. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Carcinogenesis 25 (2004) 1735-1746
33. Ikenaka Y., Yoshiji H., Kuriyama S., et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int. J. Cancer 105 (2003) 340-346
34. Martin D.C., Ruther U., Sanchez-Sweatman O.H., Orr F.W., and Khokha R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 13 (1996) 569-576
35. Kruger A., Fata J.E., and Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90 (1997) 1993-2000
36. Seo D.W., Li H., Guedez L., et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114 (2003) 171-180
37. Jung K.K., Liu X.W., Chirco R., et al. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 25 (2006) 3934-3942
38. Haviernik P., Lahoda C., Bradley H.L., et al. Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation. Oncogene 23 (2004) 9212-9219
39. Soloway P.D., Alexander C.M., Werb Z., and Jaenisch R. Targeted mutagenesis of TIMP-1 reveals that lung tumor invasion is influenced by TIMP-1 genotype of the tumor but not by that of the host. Oncogene 13 (1996) 2307-2314
40. Stetler-Stevenson M., Mansoor A., Lim M., et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 89 (1997) 1708-1715
41. Robinson S.N., Pisarev V.M., Chavez J.M., Singh R.K., and Talmadge J.E. Use of matrix metalloproteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligand-induced hematopoietic progenitor cell mobilization or engraftment. Stem Cells 21 (2003) 417-427
42. Chakrabarti S., Zee J.M., and Patel K.D. Regulation of matrix metalloproteinase-9 (MMP-9) in TNF-stimulated neutrophils: novel pathways for tertiary granule release. J. Leukoc. Biol. 79 (2006) 214-222
43. Itoh N., Nishimura H., Matsuguchi T., et al. CD8 alpha-deficient mice are highly susceptible to 5-fluorouracil-induced lethality. Clin. Diagn. Lab. Immunol. 9 (2002) 550-557
44. Osiewicz K., McGarry M., and Soloway P.D. Hyper-resistance to infection in TIMP-1-deficient mice is neutrophil dependent but not immune cell autonomous. Ann. N. Y. Acad Sci. 878 (1999) 494-496
45. Malik M., Bakshi C.S., McCabe K., et al. Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J. Immunol. 178 (2007) 1013-1020